NLE Gastrointestinal Nursing — Lower GI & Bowel DisordersSummary

IBD comprises two chronic, relapsing inflammatory disorders of unknown etiology affecting the GI tract. Crohn's disease is a transmural (full-thickness) inflammation that can affect any segment from the mouth to the anus, characterized by skip lesions (patchy, non-continuous involvement), cobblestone mucosa, and fistula/stricture formation. Ulcerative colitis affects only the colon and rectum in a continuous pattern starting at the rectum, with inflammation limited to the mucosa and submucosa. UC presents with more frequent bloody, mucoid diarrhea (10–20 stools/day), while Crohn's causes softer stools with less bleeding but more malabsorption. The critical distinction: total colectomy CURES ulcerative colitis but does NOT cure Crohn's disease (which recurs). Both conditions increase colorectal cancer risk, but UC carries higher malignancy potential.

Appendicitis results from obstruction of the appendiceal lumen (most often by a fecalith or lymphoid hyperplasia), leading to bacterial overgrowth, inflammation, ischemia, and if untreated, perforation and peritonitis. The classic presentation begins with periumbilical colicky pain that MIGRATES to the RIGHT LOWER QUADRANT, localizing at McBurney's point (midway between the umbilicus and right anterior superior iliac spine). Physical examination reveals rebound tenderness (Blumberg's sign), guarding, Rovsing's sign (RLQ pain elicited by LLQ palpation), positive psoas and obturator signs, and low-grade fever. A critical danger sign is SUDDEN RELIEF of pain followed by recurrence—this indicates rupture of the appendix. The definitive treatment is appendectomy. CRITICAL SAFETY RULES: (1) NEVER apply heat to the abdomen (increases circulation and perforation risk), (2) NEVER administer laxatives or enemas (increases peristalsis and perforation risk), (3) Limit analgesics until evaluated (per facility protocol) to prevent masking progression. Position the patient in semi-Fowler's or right side-lying with knees flexed for comfort. Pre-operative teaching includes NPO status, post-operative expectations (pain, wound care, early ambulation).

Intestinal obstruction occurs when the passage of intestinal contents is blocked. Mechanical obstruction results from a physical blockage (adhesions—most common post-operative cause; hernias; tumors; volvulus; intussusception; strictures). Functional obstruction or paralytic ileus occurs without a mechanical blockage due to impaired peristalsis (post-operative ileus, peritonitis, electrolyte imbalances, sepsis). Clinical manifestations depend on the LEVEL of obstruction: SMALL-BOWEL obstruction presents with EARLY, PROFUSE VOMITING (often bilious or feculent), cramping periumbilical pain, hyperactive bowel sounds initially (high-pitched), minimal abdominal distension, and rapid fluid/electrolyte losses leading to METABOLIC ALKALOSIS (loss of gastric HCl). LARGE-BOWEL obstruction presents gradually with progressive ABDOMINAL DISTENSION, obstipation (no stool or flatus), less prominent vomiting, and METABOLIC ACIDOSIS (loss of bicarbonate). Priority interventions include NPO status, nasogastric tube (NGT) placement with low intermittent suction for decompression, aggressive IV fluid and electrolyte replacement, and strict intake and output monitoring. STRANGULATION (vascular compromise of the bowel) is a surgical emergency presenting with fever, tachycardia, rising pain intensity, abdominal rigidity, and signs of peritonitis.

IBS is a functional disorder characterized by altered GI motility and visceral hypersensitivity WITHOUT structural or inflammatory lesions on endoscopy or imaging. It presents with chronic abdominal pain that is RELIEVED BY DEFECATION (key distinguishing feature), bloating, and altered bowel habits. The Rome IV criteria classify IBS into subtypes: IBS-D (diarrhea-predominant), IBS-C (constipation-predominant), IBS-M (mixed type), and IBS-U (unspecified). CRITICAL DISTINCTIONS: IBS does NOT produce blood in stool, weight loss, nocturnal symptoms, or fever—these are RED FLAGS indicating organic disease (IBD, colorectal cancer, diverticulitis) requiring investigation. Management is symptom-focused and multifaceted: dietary modification (identifying trigger foods, especially those high in FODMAPs—fermentable oligosaccharides, disaccharides, monosaccharides, and polyols); stress management (cognitive-behavioral therapy, mindfulness); regular meal patterns and exercise; and symptom-targeted pharmacotherapy (antispasmodics for cramping, loperamide for diarrhea, osmotic laxatives or lubiprostone for constipation). Reassurance and patient education about the benign but chronic nature of IBS reduce anxiety.

Diverticulosis refers to the presence of small outpouchings (diverticula) of colonic mucosa, typically in the SIGMOID COLON, resulting from low-fiber diet, chronic constipation, and elevated intraluminal pressure over decades. Most persons with diverticulosis are asymptomatic. Diverticulitis occurs when a diverticulum becomes inflamed or infected, presenting with acute LEFT LOWER QUADRANT (LLQ) pain, fever, leukocytosis, and altered bowel habits (constipation or diarrhea). CT imaging with oral and IV contrast is the diagnostic gold standard in acute diverticulitis. CRITICAL: Colonoscopy and barium enema are CONTRAINDICATED during acute inflammation (risk of perforation); these studies are performed 6 weeks after resolution when inflammation subsides. Management of acute uncomplicated diverticulitis includes NPO status or clear liquids, IV hydration, and broad-spectrum antibiotics (typically metronidazole plus ciprofloxacin or ceftriaxone). Once acute symptoms resolve, diet is advanced. Complications include perforation, intra-abdominal abscess, fistula formation (colovesical, cologastric), and bowel obstruction. Chronic management and PREVENTION after an episode is HIGH-FIBER DIET (25–35 g/day) and adequate fluid intake; this reduces recurrence by promoting regular bowel movements and decreasing intraluminal pressure. Notably, nuts and seeds are no longer restricted per current guidelines.

Peritonitis is inflammation of the peritoneum caused by perforation of a hollow viscus (ruptured appendix, perforated peptic ulcer, perforated diverticulum, strangulated and necrotic bowel) or continuous ambulatory peritoneal dialysis (CAPD). Bacterial and GI contents spill into the peritoneal cavity, causing a life-threatening infection and septic shock if untreated. Clinical manifestations include a RIGID, BOARD-LIKE ABDOMEN (acute muscle rigidity from peritoneal irritation), severe diffuse abdominal pain, exquisite rebound and guarding tenderness, ABSENT OR DIMINISHED BOWEL SOUNDS (paralytic ileus), fever, tachycardia, tachypnea, and rapid progression to hypotension and shock. Laboratory findings show elevated WBC, elevated CRP, and positive blood cultures. Imaging (abdominal X-ray, CT) may reveal free air under the diaphragm if perforation is recent. This is a SURGICAL EMERGENCY. Priority nursing interventions include: (1) NPO status immediately, (2) Establish two large-bore IVs and begin aggressive crystalloid fluid resuscitation to reverse hypovolemia and prepare for surgery, (3) Insert NGT for gastric decompression (high risk of aspiration), (4) Obtain blood cultures, then administer broad-spectrum IV antibiotics immediately (do NOT wait for culture results—empiric coverage for gram-negatives and anaerobes, e.g., piperacillin-tazobactam or cefepime + metronidazole), (5) Position semi-Fowler's to localize fluid to the pelvis and improve respiratory effort, (6) Monitor vitals continuously for shock progression, (7) Prepare for emergent surgical source control. Post-operative care focuses on wound management, continuation of antibiotics, pain management, and monitoring for complications (anastomotic leak, abscess).

An ostomy is a surgically created opening (stoma) in the abdominal wall that diverts stool bypass the normal rectum (colostomy) or small intestine (ileostomy). A colostomy may be temporary (diverting loop colostomy during acute diverticulitis or trauma) or permanent (end colostomy after colectomy for cancer or familial polyposis). Ileostomy is typically permanent (after total proctocolectomy for UC or familial adenomatous polyposis). STOMA ASSESSMENT: A healthy stoma is PINK to RED, MOIST, and PROTRUDES slightly above skin level (approximately 1–2 cm). IMMEDIATELY REPORT a stoma that is DARK, DUSKY, BLACK, or PALE (indicates ischemia or necrosis—a surgical emergency). NORMAL STOMA DOES NOT HAVE SENSATION—the patient does not feel it. ILEOSTOMY vs. COLOSTOMY OUTPUT: Ileostomy output is CONTINUOUS, LIQUID, and ENZYME-RICH (contains active proteolytic and lipolytic enzymes), making it highly corrosive to peristomal skin and causing rapid breakdown if not protected meticulously. Ileostomy patients have HIGH RISK of DEHYDRATION and ELECTROLYTE IMBALANCE (Na+, K+, Cl−, HCO3−) because the small intestine normally absorbs water and electrolytes. Colostomy output varies by location: ascending colostomy = liquid, transverse = pasty, descending/sigmoid = more formed and sometimes can be regulated by irrigation (similar to normal defecation pattern). APPLIANCE MANAGEMENT: Pouches are changed every 3–7 days or when leaking (to prevent skin erosion). Empty the pouch when it is 1/3 to 1/2 full (to prevent tension on the seal and leakage). Appliance opening should be only 1/8 inch (approximately 3 mm) larger than the stoma to prevent skin exposure. Peristomal skin care includes gentle cleansing with warm water (no soaps), thorough drying, use of skin barriers (wafers, pastes), and moisturizers as needed. HIGH-OUTPUT ILEOSTOMY COMPLICATIONS: Peristomal dermatitis, ileostomy blockage (from high-fiber foods—patients should chew well, avoid nuts/seeds initially, and stay well hydrated), and nutritional deficiencies (B12, fat-soluble vitamins, iron). PATIENT EDUCATION: Body-image concerns are significant—many patients grieve the loss of normal bowel function and worry about odor, seepage, and social embarrassment. Nursing support includes normalizing the experience, involving the ostomy nurse specialist, peer support groups (Philippine Colorectal Cancer Association, local ostomy clubs), and gradual return to activities. Dietary teaching emphasizes the importance of chewing well, spacing meals, staying hydrated (ileostomy requires extra fluid intake to compensate for increased fecal losses), and gradually reintroducing foods to identify gas-forming (beans, cruciferous vegetables, carbonated drinks) and odor-producing foods (eggs, asparagus, garlic, onions) as tolerated. Teach about appliance changes, carrying supplies when traveling, and sexual function (with appropriate lubrication and positioning to prevent appliance dislodgment).

Pharmacological management of IBD is escalated based on disease severity and response. AMINOSALICYLATES (5-ASA): Sulfasalazine 2–4 g/day in divided doses and mesalamine are first-line agents for mild to moderate UC and Crohn's disease. SULFASALAZINE COUNSELING: Take WITH FOOD and plenty of FLUIDS (decreases GI upset and improves absorption); supplement with FOLIC ACID (sulfasalazine impairs folate absorption, increasing miscarriage and birth defect risks—critical for women of childbearing age); expect ORANGE-YELLOW urine and stool discoloration (harmless); report signs of sulfonamide allergy (rash, fever, jaundice). Monitor CBC and liver function periodically. CORTICOSTEROIDS: Prednisone (oral) or IV hydrocortisone for acute flares. Steroids suppress inflammation rapidly but are NOT maintenance therapy due to Cushingoid effects (weight gain, moon facies, acne, hyperglycemia, osteoporosis, mood disturbances, infection risk). NEVER abruptly stop steroids—always TAPER to allow HPA axis recovery and prevent Addisonian crisis. IMMUNOMODULATORS: Azathioprine (AZA), 6-mercaptopurine (6-MP), and methotrexate are steroid-sparing agents used in moderate-to-severe disease. They take 8–12 weeks to become effective, requiring patient counseling about delayed onset. CRITICAL: Monitor CBC monthly initially and then every 3 months (risk of bone marrow suppression, leukopenia, thrombocytopenia); monitor LFTs (hepatotoxicity); counsel women of childbearing age about teratogenicity (use contraception). BIOLOGICS (Anti-TNF agents): Infliximab (IV) and adalimumab (subcutaneous) are monoclonal antibodies against tumor necrosis factor-alpha, highly effective in moderate-to-severe disease and for fistula management in Crohn's. MANDATORY SCREENING BEFORE STARTING BIOLOGICS: Test for latent tuberculosis (TST/QuantiFERON-Gold), hepatitis B (HBsAg, anti-HBc), and hepatitis C serology. Active TB or viral hepatitis is a contraindication. ADVERSE EFFECTS: Infusion reactions (fever, chills, chest discomfort—slow infusion, premedicate with acetaminophen and antihistamine); increased infection risk (opportunistic infections, TB reactivation, fungal infections—counsel patient to report fever, cough, shortness of breath); rarely, autoimmune phenomena (lupus-like reaction, demyelinating disease). NURSING RESPONSIBILITIES: Ensure pre-treatment screening is complete; educate patient about infection surveillance; monitor for infusion reactions; document response and adherence.

Constipation and diarrhea represent opposite ends of the bowel function spectrum and are common presentations in Filipino healthcare settings. CONSTIPATION: Defined as infrequent (fewer than 3 stools per week for adults), difficult, or incomplete evacuation of hard, dry stools. Etiologies include low dietary fiber, inadequate fluid intake, physical inactivity, delayed bowel reflex (ignoring the urge), medications (opioids, anticholinergics, iron supplements), hormonal changes (pregnancy, hypothyroidism), neurological conditions (Parkinson's, spinal cord injury), and mechanical obstruction. Complications of chronic constipation include fecal impaction, abdominal pain, hemorrhoids, anal fissures, and megacolon. MANAGEMENT: Establish a regular toileting routine (preferably 20–30 minutes post-meal to take advantage of the gastrocolic reflex); increase dietary fiber gradually to 25–35 g/day (rapid increases cause bloating and gas); ensure adequate fluid intake (2–3 L/day); encourage daily physical activity; address medication side effects. Pharmacological options are escalated: BULK-FORMING AGENTS (psyllium, methylcellulose) absorb water and increase stool volume—use as FIRST-LINE and require adequate fluids (risk of impaction if fluids are insufficient); OSMOTIC LAXATIVES (lactulose, polyethylene glycol, magnesium citrate) draw water into the lumen and soften stool—slower onset (12–72 hours) but safer for chronic use; STIMULANT LAXATIVES (bisacodyl, senna) increase peristalsis and secretion—should NOT be used long-term (risk of dependence, electrolyte imbalance, melanosis coli). TEACH AGAINST CHRONIC LAXATIVE DEPENDENCE. Digital disimpaction may be necessary for fecal impaction. DIARRHEA: Defined as three or more loose/liquid stools per day for at least 2 consecutive days. Etiologies include infections (viral—rotavirus, norovirus; bacterial—Salmonella, Shigella, Campylobacter; parasitic), inflammatory conditions (IBD, celiac disease), medications (antibiotics causing Clostridioides difficile infection; laxatives; chemotherapy), malabsorption, lactose intolerance, and functional IBS. COMPLICATIONS (especially in vulnerable populations—infants, elderly, immunocompromised): DEHYDRATION (loss of body fluids), HYPOKALEMIA (loss of potassium → muscle weakness, cardiac arrhythmias), HYPONATREMIA (loss of sodium → cerebral edema, seizures), and METABOLIC ACIDOSIS (loss of bicarbonate → pH disturbance). MANAGEMENT PRIORITIES: (1) FLUID AND ELECTROLYTE REPLACEMENT—start with oral rehydration solution (ORS) containing glucose and electrolytes (World Health Organization formula: sodium 75 mEq/L, potassium 20 mEq/L, chloride 65 mEq/L, glucose 75 mmol/L, osmolarity 245 mOsm/L; examples in the Philippines: Gatorade, coconut water, or WHO ORS packets). IV fluid replacement (normal saline or Ringer's lactate) is needed if severe dehydration or inability to tolerate oral intake. (2) TREAT underlying cause—identify and treat infection (appropriate antibiotics, avoiding antimotility agents); manage IBD with anti-inflammatory therapy; address food intolerance. (3) ANTIMOTILITY AGENTS (loperamide, diphenoxylate) should be AVOIDED in suspected infectious diarrhea with fever or bloody stools (risk of prolonging infection, toxic megacolon in UC, worsening HUS in Shiga-toxin producing E. coli). (4) NUTRITION—progress diet as tolerated (BRAT diet—bananas, rice, applesauce, toast; then soft, bland foods). (5) PERISTOMAL/PERIANAL SKIN CARE—apply protective ointment (zinc oxide, petroleum jelly) to prevent excoriation from repeated loose stools. NURSING DIAGNOSES (NANDA): Diarrhea (IBS, infection, IBD), Constipation (decreased mobility, opioids, low fiber), Ineffective gastrointestinal tissue perfusion (dehydration risk), Risk for impaired skin integrity (peristomal breakdown), Deficient fluid volume (acute diarrhea).

Hemorrhoids are dilated rectal and/or anal veins (varices) resulting from chronic straining, constipation, prolonged sitting, pregnancy, portal hypertension, or familial predisposition. They are classified as INTERNAL (above the pectinate/dentate line—innervated by visceral nerves, hence painless unless thrombosed) or EXTERNAL (below the pectinate line—innervated by somatic nerves, hence painful). INTERNAL HEMORRHOIDS present with painless bright-red blood on stool or toilet paper, mucoid discharge, and prolapse (protrusion through the anus, especially with straining; may auto-reduce or require manual reduction). Grading: Grade I (no prolapse), Grade II (prolapse with spontaneous reduction), Grade III (prolapse requiring manual reduction), Grade IV (irreducible prolapse). EXTERNAL HEMORRHOIDS present with pain, itching, palpable swelling, and visible veins at the anal verge. Acute thrombosis of an external hemorrhoid causes sudden severe pain and a palpable bluish mass. DIAGNOSTICS: Visual inspection and digital rectal examination for external hemorrhoids; anoscopy or flexible sigmoidoscopy for internal hemorrhoids and to exclude other anorectal pathology (fissures, polyps, malignancy). CONSERVATIVE MANAGEMENT (first-line and appropriate for most patients): High-fiber diet and adequate fluids to soften stool and reduce straining; stool softeners (docusate); sitz baths (3–4 times daily, especially after defecation; 10–15 minutes in warm water to relieve pain and promote healing); topical treatments (hydrocortisone cream, anesthetic ointment—benzocaine, lidocaine; witch hazel for astringent effect); avoidance of prolonged sitting and straining. Pregnancy-related hemorrhoids often improve post-partum. PROCEDURAL INTERVENTIONS (for persistent or severe hemorrhoids): RUBBER-BAND LIGATION (outpatient procedure; band is placed at the base of internal hemorrhoid, cutting off blood supply; hemorrhoid sloughs after 7–10 days); SCLEROTHERAPY (injection of sclerosing agent); INFRARED COAGULATION; HEMORRHOIDECTOMY (surgical excision for Grade III–IV or failed conservative/procedural management; more effective but more painful post-operatively). POST-OPERATIVE HEMORRHOIDECTOMY TEACHING: Pain is EXPECTED and often SEVERE for the first 2 weeks (manage with prescribed analgesia, sitz baths, stool softeners); the first bowel movement is particularly anxiety-provoking (reassure patient, instruct pre-medication 30 minutes before anticipated defecation); adequate pain relief promotes early mobilization and prevents complications (urinary retention). Expect bloody drainage initially and gradual healing over 3–6 weeks. Risk of infection or postoperative bleeding warrants prompt medical attention.

Colorectal cancer (CRC) is the third most common cancer in the Philippines (Philippine Cancer Registry) and is largely preventable through screening and early detection. RISK FACTORS: Age (≥50 years—average risk; earlier screening if family history or personal history of polyps); long-standing IBD (especially UC), which increases CRC risk 2–3 times; personal or family history of CRC or adenomatous polyps; dietary risk factors (low fiber, high red and processed meat, high fat); obesity; smoking; excessive alcohol; sedentary lifestyle; hereditary syndromes (Lynch syndrome, familial adenomatous polyposis). RED-FLAG SYMPTOMS warranting investigation: (1) Change in bowel habit lasting >3 weeks (sudden constipation, diarrhea, or alternating pattern); (2) Rectal bleeding or visible blood in stool (distinguishing from obvious hemorrhoids requires evaluation); (3) Unexplained iron-deficiency anemia (suggests chronic occult GI bleeding, common with right-sided CRC); (4) Unintentional weight loss >10% over 6 months; (5) Abdominal pain or discomfort, especially if new onset; (6) Sense of incomplete evacuation or tenesmus (straining); (7) Palpable abdominal mass. LOCATION AND PRESENTATION: LEFT-SIDED (rectum, sigmoid colon) tumors often cause obstructive symptoms (change in caliber of stool, partial obstruction, left lower quadrant pain) and visible bleeding. RIGHT-SIDED (cecum, ascending colon) tumors frequently present late with anemia and nonspecific symptoms (fatigue, weight loss, RUQ pain) because the bowel is wider and the tumor can grow large before causing obstruction. SCREENING (Philippine Department of Health and international guidelines): Average-risk individuals ≥50 years: FECAL OCCULT BLOOD TEST (FOBT) annually OR COLONOSCOPY every 10 years (gold standard) OR COMPUTED TOMOGRAPHIC COLONOGRAPHY (CT colonography). HIGH-RISK individuals (family history, IBD, prior polyps) should BEGIN screening at 40 years or 10 years before the youngest age at which a relative was diagnosed, and may need MORE FREQUENT intervals. COLONOSCOPY is the definitive diagnostic and therapeutic tool (allows visualization, biopsies, and polypectomy—removal of polyps before malignant transformation). NURSING ROLE: Educate patients about screening benefits, address misconceptions and embarrassment, prepare for colonoscopy (bowel prep, NPO), support during procedure anxiety, and reinforce follow-up recommendations. Early detection of adenomatous polyps and CRC at localized stages dramatically improves 5-year survival (Stage I/II ~90% vs. Stage IV ~14%).

Toxic megacolon is a fulminant, life-threatening complication of ulcerative colitis (and rarely Crohn's colitis) characterized by acute colonic dilation (>6 cm on imaging), severe systemic toxicity, and high mortality if untreated. It typically occurs during an acute severe flare of UC and can be precipitated or worsened by antimotility agents (loperamide), antidiarrheals, or colonoscopy during acute inflammation. PATHOPHYSIOLOGY: Severe mucosal inflammation and ulceration, combined with loss of colonic muscle tone, results in acute, massive dilation of the colon. The inflamed, thinned colonic wall becomes ischemic and necrotic, at imminent risk of perforation. Bacterial translocation and endotoxemia follow, precipitating septic shock. CLINICAL MANIFESTATIONS: ABDOMINAL DISTENSION (rapidly progressive, marked), severe abdominal pain and tenderness, FEVER (often >38.5°C), TACHYCARDIA (>120 bpm), TACHYPNEA, HYPOTENSION, and signs of shock (altered mental status, oliguria, cool/clammy skin). Diarrhea may paradoxically DECREASE or stop as peristalsis fails. Laboratory findings: severe leukocytosis (WBC >15,000/μL), hypokalemia, hyponatremia, elevated CRP/ESR, elevated lactate, and positive blood cultures if sepsis develops. IMAGING: Abdominal X-ray shows colonic dilation >6 cm, air-fluid levels, and thumbprinting (from mucosal edema); CT with IV contrast confirms diagnosis and assesses perforation risk. MANAGEMENT IS URGENT: (1) NPO immediately; establish aggressive IV access (two large-bore IVs); begin rapid crystalloid infusion (NS or LR) to restore intravascular volume and prepare for surgery. (2) Insert NGT for gastric decompression (reduce distension and aspiration risk). (3) Blood cultures, then STAT broad-spectrum IV antibiotics covering gram-negatives and anaerobes (do NOT delay). (4) Correct electrolyte abnormalities (K+, Na+, Mg2+) and metabolic acidosis. (5) STOP ALL ANTIMOTILITY AGENTS and anti-inflammatory medications (steroids may be continued at current doses but are not used to treat acute toxic megacolon). (6) Position semi-Fowler's to ease breathing and localize fluid. (7) URGENT surgical consultation—most patients with toxic megacolon require EMERGENCY COLECTOMY (total abdominal colectomy with ileostomy) to remove the diseased colon and prevent perforation/death. (8) ICU monitoring post-operatively with continued antibiotics, fluid resuscitation, pain management, and surveillance for complications (anastomotic leak, sepsis, ARDS). MORTALITY: Despite aggressive management, mortality remains 10–30%, higher if perforation has already occurred. PREVENTION: Aggressive treatment of acute UC flares with IV corticosteroids and/or biologics, AVOIDING antimotility agents and NSAIDs, and urgent treatment initiation reduce toxic megacolon risk.

Applying the nursing process and NANDA-I nursing diagnoses to lower GI disorders ensures systematic, evidence-based assessment, planning, intervention, and evaluation. ACUTE PRESENTATIONS (e.g., appendicitis, peritonitis, acute IBD flare, obstruction, toxic megacolon) require LIFE-THREATENING diagnosis prioritization: (1) INEFFECTIVE TISSUE PERFUSION (all affected body systems)—from sepsis, peritonitis, or hemorrhage; manifested by hypotension, tachycardia, altered mental status, oliguria. Interventions: aggressive fluid resuscitation, vasopressors if needed, prepare for surgery, continuous monitoring. (2) RISK FOR INFECTION / SEPSIS—from perforation, peritonitis, or translocation; manifested by fever, elevated WBC, positive cultures. Interventions: obtain blood cultures, administer broad-spectrum antibiotics immediately, maintain sterile technique, isolate if C. difficile. (3) ACUTE PAIN—from inflammation, obstruction, or surgery; manifested by verbal/nonverbal pain signals, guarding, facial grimacing. Interventions: assess pain regularly, administer analgesics (respecting facility protocols for acute abdomen assessment), comfort measures (positioning, heat/cold as appropriate). (4) DEFICIENT FLUID VOLUME—from diarrhea, vomiting, or surgical fluid shifts; manifested by tachycardia, hypotension, decreased skin turgor, dry mucous membranes, thirst. Interventions: establish IV access, fluid resuscitation (calculate based on losses and maintenance), monitor I&O and labs (electrolytes, BUN/creatinine). (5) IMBALANCED NUTRITION, LESS THAN BODY REQUIREMENTS—from malabsorption (Crohn's), chronic diarrhea (UC, IBS), or NPO status; manifested by weight loss, lab malnutrition markers (albumin, prealbumin, ferritin), muscle wasting. Interventions: nutritional assessment, dietitian referral, high-protein/high-calorie diet as tolerated, TPN if needed, monitor albumin/prealbumin. CHRONIC PRESENTATIONS (IBD remission, IBS, diverticulosis, hemorrhoids) shift prioritization to psychological and social needs (Maslow's higher levels): (6) ANXIETY / INEFFECTIVE COPING—related to chronic disease, fear of complications (e.g., ostomy in UC patients), or uncertainty; manifested by verbalized worry, restlessness, sleep disruption. Interventions: provide psychoeducation about disease and treatment, teach relaxation/coping strategies, refer to mental health services or support groups, normalize experiences. (7) DISTURBED BODY IMAGE—particularly in ostomy patients or those with IBD flares; manifested by avoidance of mirror, negative self-talk, withdrawal from social activities. Interventions: encourage verbalization of feelings, involve ostomy nurse specialist, support gradual return to self-care and socialization, refer to peer support groups. (8) INEFFECTIVE SEXUAL FUNCTION / SEXUAL DYSFUNCTION—from disease or medications (steroids → libido ↓, certain biologics); manifested by decreased sexual desire, erectile dysfunction, or communication difficulties with partner. Interventions: assess openly in a nonjudgmental manner, provide education about disease effects and management, refer to sex therapist if needed, discuss medication alternatives with provider. (9) DEFICIENT KNOWLEDGE—about disease process, triggers, medication adherence, dietary modifications, ostomy care; manifested by questions, misconceptions, nonadherence. Interventions: structured patient education, teach-back method, written resources, involve family/caregivers. (10) INEFFECTIVE HEALTH MAINTENANCE—related to lifestyle factors (stress, diet, exercise, adherence); manifested by medication non-adherence, poor dietary choices, sedentary behavior. Interventions: assess barriers to adherence, develop realistic action plans with patient input, provide incentives (e.g., reminders, family support), reinforce benefits of adherence. MASLOW-BASED PRIORITIZATION FRAMEWORK: (Level 1—Physiological Needs, most urgent): Airway protection, circulation, breathing, pain, elimination, nutrition, elimination of waste, maintaining fluid/electrolyte balance. Acute abdomen and sepsis patients require Level 1 interventions (fluids, antibiotics, surgery). (Level 2—Safety Needs): Protection from injury, predictability, maintaining therapeutic protocols (e.g., NPO for appendicitis, medication timing). (Level 3—Belonging/Love Needs): Family involvement in care planning, peer support groups, maintaining relationships. (Level 4—Esteem Needs): Recognizing patient autonomy and preferences, supporting self-efficacy. (Level 5—Self-Actualization): Helping patients find meaning in their chronic disease journey, facilitating goal-setting. DOCUMENTATION: Use SOAP format (Subjective-Objective-Assessment-Plan) aligned with facility standards, documenting pain assessments, fluid/electrolyte status, nutrition, psychosocial responses, and interventions/outcomes. COMPLIANCE WITH RA 9173 (Philippine Nursing Act): All nursing diagnoses and interventions must be evidence-based, aligned with standards of care, delegated appropriately (some tasks may be delegated to CNAs under RN supervision), and documented thoroughly for medicolegal protection.

Both Crohn's disease and ulcerative colitis are chronic, relapsing inflammatory conditions that increase colorectal cancer risk. However, their distinct anatomical involvement (Crohn's transmural anywhere vs. UC mucosal/continuous colon/rectum) leads to different complications: Crohn's → fistulas, strictures, malabsorption, perianal disease; UC → toxic megacolon, massive bleeding, continuous ulceration. This distinction determines surgical outcomes (UC is cured by colectomy; Crohn's recurs) and pharmacological strategies (same first-line 5-ASA and corticosteroids, but biologic selection may differ).

Many lower GI conditions present acutely (appendicitis, peritonitis, intestinal obstruction, acute IBD flare) demanding immediate physiological stabilization (Level 1 Maslow: airway, breathing, circulation, pain, elimination). As acute crisis resolves and patient enters chronic/remission phase, nursing priorities shift to Level 3–5 needs (belonging through peer support, esteem through body-image work, self-actualization through disease acceptance and lifestyle modification). For example, an acute colitis patient requiring emergent colectomy and temporary ileostomy initially needs fluid/electrolyte restoration and pain management; once stable, the focus becomes body-image support, sexual function counseling, and long-term diet/medication adherence.

Dietary fiber plays contrasting roles: in diverticulosis PREVENTION and CHRONIC MANAGEMENT, HIGH-FIBER diet (25–35 g/day) and fluids reduce intraluminal pressure and straining, preventing recurrent diverticulitis. DURING ACUTE DIVERTICULITIS, bowel rest (NPO or clear liquids) and LOW-FIBER diet allow inflammation to settle before transitioning back to HIGH-FIBER for prevention. In constipation, HIGH-FIBER diet and fluids are primary management. In IBS, FODMAP reduction identifies and avoids trigger foods causing bloating/cramping while pain relief occurs with defecation. In acute IBD flares, LOW-RESIDUE (low-fiber), high-protein, high-calorie diet reduces bowel stimulation; in remission, balanced nutrition with adequate fiber supports mucosal healing.

Diarrhea from any cause (IBD, IBS, infectious, osmotic laxative overuse) results in losses of water, sodium, potassium, chloride, and bicarbonate. The CONSEQUENCE depends on the RATE and VOLUME of loss and patient VULNERABILITY: ileostomy produces continuous liquid output rich in electrolytes and enzymes, requiring vigilant replacement (extra fluids, salt, vitamins); acute IBD flares with 10–20 bloody stools/day cause rapid DEHYDRATION, HYPOKALEMIA (→ cardiac dysrhythmias, muscle weakness), and METABOLIC ACIDOSIS (bicarbonate loss). Elderly, infants, and immunocompromised patients are at HIGHEST RISK of complications. Priority intervention is always fluid/electrolyte replacement with ORS or IV fluids, not antimotility agents.

IBD management follows an escalation strategy: mild-moderate disease starts with 5-ASA agents (sulfasalazine, mesalamine) that reduce mucosal inflammation locally. If inadequate response, corticosteroids (prednisone, IV hydrocortisone) are added for acute flares, but are tapered to prevent long-term Cushingoid effects. For steroid dependence or severe disease, immunomodulators (azathioprine, 6-MP, methotrexate) provide steroid-sparing effect but require 8–12 weeks and closer monitoring (CBC, LFTs). For moderate-to-severe disease refractory to above or with complications (fistulas in Crohn's), biologics (infliximab, adalimumab—anti-TNF agents) are initiated. Each escalation requires more intensive monitoring (biologics require TB and hepatitis B screening), carries additional risks (biologics increase infection risk), and demands greater patient adherence. The goal is remission with minimal medication burden and side effects.

Intestinal obstruction manifests differently depending on anatomical LEVEL, which determines SEQUELAE: SMALL-BOWEL obstruction (proximal ileum most often) presents early with PROFUSE VOMITING of bilious content, causing rapid loss of gastric HCl, Na+, K+, Cl− → METABOLIC ALKALOSIS and HYPOKALEMIA (cardiac risk). Cramping periumbilical pain, hyperactive bowel sounds initially (then absent as peritonitis/strangulation develops), and MINIMAL distension characterize proximal small-bowel obstruction (narrow lumen, proximal dilation). LARGE-BOWEL obstruction (sigmoid colon most often) presents gradually with PROGRESSIVE ABDOMINAL DISTENSION, obstipation (no stool or flatus), LESS prominent vomiting (competent ileocecal valve prevents reflux initially), and METABOLIC ACIDOSIS (loss of bicarbonate from diarrhea before complete obstruction). STRANGULATION (vascular compromise) can occur at any level; it is a SURGICAL EMERGENCY manifesting with fever, severe pain, rigidity, tachycardia, and signs of sepsis/shock.

Appendicitis follows a predictable clinical progression: early inflammation (periumbilical pain, mild symptoms) → mucosal ulceration and transmural involvement (pain migration to RLQ, fever, rebound tenderness, leukocytosis) → ischemia/necrosis → rupture (SUDDEN PAIN RELIEF followed by recurrence with peritonitis signs—rigid abdomen, absent bowel sounds, profound shock). RUPTURE converts a surgical urgency into a surgical EMERGENCY with high mortality if not immediately treated. The critical nursing roles are: (1) recognizing early signs (appendicitis mimics many acute abdominal conditions; high index of suspicion is needed), (2) preventing rupture through NPO status, avoiding heat/laxatives/enemas that accelerate inflammation, and (3) alerting the surgical team for immediate appendectomy. Post-rupture, broad-spectrum antibiotics, aggressive fluid resuscitation, and emergency surgery are required to treat peritonitis/sepsis.

An ostomy is not merely a surgical change in bowel function but a significant life-altering event affecting the patient across biological, psychological, and social domains. BIOLOGICALLY, ileostomy output is liquid, continuous, enzyme-rich, and uncontrollable—requiring meticulous peristomal skin care, dietary modifications, and vigilant fluid/electrolyte/vitamin replacement. PSYCHOLOGICALLY, patients grieve the loss of normal bowel function, experience anxiety about odor/leakage/visible appliance, fear sexual dysfunction, and may withdraw socially. SOCIALLY, concerns about workplace accidents, dating/intimacy, travel, and social activities arise. ADAPTATION is facilitated through: (1) early ostomy nurse specialist involvement, (2) peer support groups (connecting with others who have ostomies normalizes the experience), (3) gradual exposure to self-care (changing the pouch independently builds self-efficacy), (4) sexual counseling and reassurance that intimacy is possible with appropriate positioning/timing, (5) recognition that adaptation is a process taking months to years—initial shock and denial often give way to acceptance and reintegration. Nurses play a crucial role in facilitating this adaptation by providing nonjudgmental support, realistic expectations, and ongoing psychoeducation.

Colonoscopy is the gold-standard diagnostic and therapeutic tool for lower GI pathology (CRC screening, polyp removal, biopsy of inflammatory lesions, evaluation of bleeding). However, TIMING and CLINICAL CONTEXT are critical for SAFETY: DURING ACUTE DIVERTICULITIS, colonoscopy is CONTRAINDICATED (inflamed, friable mucosa at high risk of perforation). DURING ACUTE TOXIC MEGACOLON (UC fulminant flare), colonoscopy is CONTRAINDICATED (further distension and perforation risk). DURING ACTIVE IBD WITH SEVERE BLEEDING, colonoscopy is deferred until bleeding is controlled (risk of perforation during air insufflation). Conversely, colonoscopy is INDICATED and URGENT in: hemodynamic stability after acute diverticulitis resolves (6 weeks) to exclude malignancy or other pathology, stable CRC screening candidates, and evaluation of iron-deficiency anemia. PREPARATION: standard bowel prep (polyethylene glycol solution or alternative laxative regimen day before) to clear stool and allow visualization; NPO 4–6 hours pre-procedure; informed consent discussing risks (perforation ~1/1000, bleeding post-polypectomy); sedation/analgesia to reduce anxiety and discomfort.